Know Labs Adds CFO, Chief Product Officer to its C-Suite

Know Labs Inc. has bolstered its senior executive team with the additions of Steven Kent as chief product officer and Peter Conley as chief financial officer and senior vice president of Intellectual Property. Both men will play a pivotal role in guiding the company toward its goal of delivering the first U.S. Food and Drug Administration-cleared non-invasive glucose monitor.  

“Pete and Steve bring tremendous expertise that will help us refine and execute our IP strategy, product innovation, and machine learning progress,” said Phil Bosua, Know Labs CEO. “By strengthening our executive leadership team, we are better positioned to tackle the milestones needed for the FDA clearance process.”

Conley brings to his role more than 34 years of corporate finance and equity capital markets experience, more than $5 billion in equity transactions, and over 20 years of specialization in strategic IP analysis, IP development, and IP monetization. He most recently served as senior managing director and head of Intellectual Property Banking at Boustead Securities, where he provided equity financing and M&A advisory services to small-cap public companies with promising disruptive technologies and strong intellectual property. Prior to Boustead, Conley was a co-founder and chief operating officer of ipCreate, a global IP development, and innovation services company serving large multinational companies. He also served as managing director of ipCapital Venture Group, where he provided IP strategy and venture advisory services. During his career, Conley has held leadership roles at MDB Capital Group, The Analytiq Group / RDEX Research, Roth Capital Partners, and Lehman Brothers. He was on the founding team and head of Equity Capital Markets at E*Offering, the investment bank of E*Trade.

Kent is responsible for product development and clinical testing at Know Labs. He brings to the position more than 10 years of experience as an inventor, entrepreneur, and leader in medical and health-focused consumer systems. He most recently served as head of Health Partnerships and Corporate Strategy at Oura, a health technology company, supporting the company’s foundational strategy, research, development, and partnerships with leading healthcare institutions around the world, from early-stage to a global, multi-billion-dollar valuation. Previously, Kent was the founder and CEO of Invicta Medical, a medical technology company focused on sleep apnea treatment. Kent attended the University of Southern California to study economics and entrepreneurship.

“It is exciting to witness our organization grow,” said Dr. James Anderson, Know Labs chief medical officer. “I’ve been through this process several times in my career. As we get closer to FDA submission and clearance, the amount of work increases across multiple disciplines; and this requires expertise in each discipline. Having experienced and highly qualified individuals is critical for our success.”

Know Labs, Inc.’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor that provides users with real-time information on blood glucose levels.